Document is current
Any future updates will be listed below
-
Authors
Shiota, Masaki
Nemoto, Shota
Ikegami, Ryo
Tatarano, Shuichi
Kamoto, Toshiyuki
Kobayashi, Keita
Sakai, Hideki
Igawa, Tsukasa
Kamba, Tomomi
Fujimoto, Naohiro
Yokomizo, Akira
Naito, Seiji
Eto, Masatoshi
-
Funding
Funding for this research was provided by:
Astellas Investigator Sponsored Research
- License Information
-
More Information
Article History
Received: 26 June 2024
Revised: 13 August 2024
Accepted: 20 August 2024
First Online: 9 September 2024
Competing interests
: MS received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, and Bayer and research funding support from Daiichi Sankyo. SN and RI are employees of Hitachi Co. Ltd. Toshiyuki Kamoto received research funding support from Janssen Pharmaceutical, Astellas Pharma, Shin Nippon Biomedical Laboratories, Ono Pharmaceutical, Bayer, Sanofi, and Takeda Pharmaceutical. HS received honoraria from Takeda Pharmaceutical and Astellas Pharma. TI received honoraria from Janssen Pharmaceutical and Astellas Pharma. TK received honoraria from AstraZeneca and Merck. AY received honoraria from Janssen Pharmaceutical and Astellas Pharma. ME received honoraria from Takeda Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, and Astellas Pharma and research funding support from Astellas Pharma, Sanofi, and Takeda Pharmaceutical. MS is an Associate Editor at BJC Reports. He was not involved in any aspect of handling of this manuscript or any editorial decisions.
: This study was conducted in accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. Eligible patients provided written informed consent. This study was approved by the Kyushu University review board (23087-00).
